Liu T-C, Kirn D
Department of Clinical Research, Jennerex Biotherapeutics Inc., San Francisco, CA, USA.
Gene Ther. 2008 Jun;15(12):877-84. doi: 10.1038/gt.2008.72. Epub 2008 Apr 17.
The past 2 years have seen several major advances in oncolytic virotherapy. Studies on the interaction between viruses, immune responses and tumor microenvironment have provided important insight, while clinical trials have shown promise. This review summarizes key findings in this field over the past 2 years, and provides directions for future success.
在过去的两年里,溶瘤病毒疗法取得了几项重大进展。关于病毒、免疫反应和肿瘤微环境之间相互作用的研究提供了重要的见解,同时临床试验也显示出了前景。本综述总结了过去两年该领域的关键发现,并为未来的成功指明了方向。